Pharma Companies now Looking to Orphan Drugs as an Essential Revenue Stream in 2014

As of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs and the Early Access to Medicines Scheme was introduced. Key implementation of this will be a factor into further commercialisation and developments.

Based on this information SMi Group is proud to announce it will be hosting the 3rd annual conference on Orphan Drugs and Rare Diseases and bringing together leading experts and companies such as Novabiotics, Pfizer, AstraZeneca, GMP Orphan SAS, Genethon and M&C Saatchi and many more to discuss the latest developments in the market.

Benefits of Attending:

  • Hear important insights from Ian Hudson, CEO, MHRA on the Early Access to Medicines Initiative and adaptive licensing
  • Focus on enhancing development pathways, with the growth of the commercial pipeline for orphan drugs and rare diseases
  • Assess tools for consideration to gain early market access and enhance patient recruitment
  • Interactive round table discussion led by Dominic Nutt, Director of Communications, The Saatchi Cancer Initiative, M&C Saatchi on creating a culture of innovation in the field of orphan drugs and rare diseases

Key Speakers:

  • Dr Gunter Harms, Market Access & Public Affairs Directore, Shire
  • Bertram Haussle, Chaiman of the Board of Management, IGES Institut
  • Josie Godfrey, Associate Director-Highly Specialised Technologies, NICE
  • Chris Hart, Information Practice Leader, AstraZeneca
  • Anthony Hall, Co-Founder, Findacure Foundation

For more information please visit http://www.smi-online.co.uk/2014orphandrugs78.asp